Timothy L. Moore, a director at BioLife Solutions Inc., has reported the sale of 44,943 shares of the company following its recent merger with Repligen Corporation. This significant transaction, filed with the SEC, reflects changes in ownership as BioLife transitions into a new corporate structure.
The filing, dated October 8, 2026, indicates that the shares were disposed of in connection with the consummation of the merger on October 6, 2026. Under the terms of the merger agreement, each outstanding share of BioLife's common stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock.
Background
BioLife Solutions Inc. is a company involved in the production of products and services related to the preservation and storage of cells and tissues. The company operates within the electromedical and electrotherapeutic apparatus sector. Recent filings show that Moore has been actively managing his holdings, with several transactions reported in 2026 alone.
What the Filing Says
The filing states, "Reflects the disposition of shares of common stock of BioLife Solutions, Inc. in connection with the consummation on October 6, 2026 of the merger..."
Impact
This sale may affect BioLife Solutions' stock performance and investor sentiment as the company integrates with Repligen. As a director, Moore's actions could signal confidence or concerns regarding the merger's outcomes. Other stakeholders in the electromedical sector will be monitoring how this merger reshapes competitive dynamics in the market.
What's Next
The filing does not say what happens next.